Veru Inc (VERU)
Veru Inc. is a Nasdaq-listed common stock company in the healthcare sector focused on pharmaceuticals. The company is a late-stage biopharmaceutical developer working on treatments for metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS), with activities in Florida and international markets. Its portfolio includes FC2 female condom, which is designed to help protect against unplanned pregnancy and sexually transmitted infections. Veru is also advancing enobosarm, an oral selective androgen receptor modulator being studied for fat loss and muscle preservation in sarcopenic obese and overweight older patients, as well as for AR+ ER+ HER2- metastatic breast cancer. In addition, the company is developing sabizabulin for hospitalized patients with viral lung infection who are at high risk of ARDS and death. Formerly known as The Female Health Company, the business adopted the Veru Inc. name in July 2017 and is headquartered in Miami, Florida.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VERU
|
$2.67
|
10.8% Upside
|
Fair
|
$24.50
|
916.6% Upside
|
Bargain
|
Fair
|
0.0%
|
November 26, 2026
|
1.4x
|
41.262 M
|
17.527 M
|
6.1%
|
90.8%
|
-14.8
|
184.6%
|
